GlobeNewswire

Kylo Peptides Strengthens U.S.-Based Supply Chain for Research Peptides with Faster Domestic Fulfillment
22/09/2026
Sheridan, Wyoming, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ] has strengthened domestic fulfillment for research peptides, routing more order flow through one U.S. warehouse so [...]
Rendever Expands Dementia & Empathy Training With a New Mode for Family Caregivers
22/09/2026
New feature brings guidance from a family caregiver turned dementia researcher directly into the immersive training, helping families navigate a loved one's condition at home BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- [...]
Seek Labs Launches Open Impact Program at Clinton Global Initiative to Advance Therapeutic Development for Neglected Infectious Diseases
22/09/2026
New Commitment to Action will apply Seek Labs’ BioSeeker AI and Sequence Ablation Therapeutics platform to diseases historically underserved by traditional therapeutic development SALT LAKE CITY, Sept. 22, 2026 (GLOBE [...]
Ophirex Publishes Data from Phase 2 BRAVIO Trial Evaluating Intravenous Followed by Oral Varespladib for Snakebite
22/09/2026
Trial evaluated varespladib administered after antivenom across multiple snake species in India and the United States Clinically important signals of benefit observed in patients bitten by kraits and copperheads CORTE [...]
New Study Reveals When College Students at Risk for Suicide Begin to Improve in Virtual Therapy
22/09/2026
Peer-reviewed TimelyCare research published in DIGITAL HEALTH finds many students show early improvement while underscoring the need for continued suicide risk monitoring. Fort Worth, TX, Sept. 22, 2026 (GLOBE NEWSWIRE [...]
Eclipse Energy and Wood Validate Pathway to Low-Cost, Ultra-Low-Carbon Hydrogen from Depleted Oil Reservoirs
22/09/2026
RenovaStrata™ H2 achieves modeled LCOH as low as $0.56/kg and carbon intensity of 0.076 kgCO₂e/kgH₂, reinforcing potential for commercial-scale, ultra-low-carbon hydrogen HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- [...]
Porch Light Health and CBHC Expand Access to Methadone Treatment in Northern Colorado
22/09/2026
New medication units in Fort Collins and Greeley bring methadone treatment into existing Porch Light Health outpatient addiction clinics DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- As drug overdose deaths continue to [...]
X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
22/09/2026
WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- X-Chem, a global leader in innovative drug discovery services, announced the achievement of a milestone following Relay Therapeutics’ initiation of a Phase 3 clinical [...]
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
22/09/2026
ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028 [...]
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
22/09/2026
First patient marks Polyrizon’s transition into a clinical-stage company. The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in patients with [...]
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
22/09/2026
MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
22/09/2026
New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Dataset [...]
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
22/09/2026
– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome – Fast Track Designation Facilitates Development and [...]
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
22/09/2026
The FDA recommended that Compass conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig. Compass does not believe that a new trial is warranted prior to submitting a BLA based on the [...]
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
22/09/2026
Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months Clinically relevant improvement in social anxiety over [...]
Elevar Therapeutics Receives FDA Conditional Acceptance of LYRFIGTU as Brand Name for Lirafugratinib
22/09/2026
In March, the FDA granted Priority Review of Lyrfigtu (lirafugratinib); PDUFA date of September 25, 2026 Lyrfigtu (lirafugratinib) achieved a 46% ORR, in CCA patients with FGFR2 fusion or other rearrangement Fort Lee, N [...]
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
22/09/2026
DOYLESTOWN, Pa., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of [...]
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
22/09/2026
Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicine Eos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for [...]
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
22/09/2026
Agreement provides dedicated commercial channel for REZENOPY ™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States According to IQVIA data [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum